Get Ready for Your 'Daily Glitch'—The NYSE, WSJ and United Were Just the Beginning
“Glitch” is clearly the word of the moment, after a series of pesky little technical problems forced United Airlines to ground flights, halted New York Stock Exchange trading and took down The Wall Street Journal website homepage all on the same day. If that wasn’t enough technical trouble, Seattle’s 911 system went down briefly. And a couple of NASA spacecraft also suffered “glitches” in recent days.
We deal routinely with glitches these days — a Wi-Fi connection goes down, an app freezes, a plug-in (usually Shockwave) stops responding, an email doesn’t load properly — which may help explain why, aside from lots of grumbling from delayed airline passengers, the reaction to Wednesday’s glitches was rather muted. The NYSE problems were reportedly caused by a “configuration issue” after a software update and United blamed its problem on “degraded network connectivity.” We see those issues every day, just not on as large a scale.
But that’s the problem.
At the risk of sounding like a high school term paper, let us note that the Merriam-Webster definition of glitch is “an unexpected and usually minor problem; especially: a minor problem with a machine or device (such as a computer).” The full definition describes it as a minor problem that causes a temporary setback.
Sure, Wednesday’s setbacks were all temporary. The Wall Street Journal site came back up quickly. Seattle’s 911 service was restored. Action on the NYSE itself was stopped for nearly four hours, but even then traders were still able to buy and sell NYSE-listed stocks on other exchanges. United grounded about 3,500 flights, which meant some people missed a wedding or a crucial business meeting. That will take time to sort out, but it will get sorted out.
In aggregate, though, the problems add up — and the word “glitch” only minimizes what can be much bigger, more serious issues..
Stock exchanges have suffered from a series of stoppage-causing glitches in recent years, pointing to the value of having trading spread across numerous exchanges. United’s tech breakdown “marked the latest in a series of airline delays and cancellations in the last few years that experts blame on massive, interconnected computer systems that lack sufficient staff and financial backing,” the Los Angeles Times reports. Just ask any of the roughly 400,000 United passengers whose travel plans were messed up if this was a little glitch. Or maybe check with the engineers who had to troubleshoot and rebuild the HealthCare.gov site after its glitch-laden launch.
It may be some relief that these latest outages weren’t the result of external attacks, but as sociologist Zeynep Tufecki, an assistant professor at the School of Information at the University of North Carolina, writes at The Message, “The big problem we face isn’t coordinated cyber-terrorism, it’s that software sucks. Software sucks for many reasons, all of which go deep, are entangled, and expensive to fix.”
These foul-ups are now mundane, and to some extent they may be inevitable as we rely more and more on complicated computer systems in every aspect of our lives. That’s the real issue, and it’s a lot bigger than a glitch.
Chart of the Day: High Deductible Blues
The higher the deductible in your health insurance plan, the less happy you probably are with it. That’s according to a new report on employer-sponsored health insurance from the Kaiser Family Foundation and the Los Angeles Times.
Chart of the Day: Tax Cuts and the Missing Capex Boom
Despite the Republican tax overhaul, businesses aren’t significantly increasing their capital expenditures. “The federal government will have to borrow an added $1 trillion through 2027 to pay for the corporate tax breaks,” says Bloomberg’s Mark Whitehouse. “So far, it’s hard to see what the country is getting in return.”
Chart of the Day: 2019’s Lobbying Leaders
Roll Call reports that trade, infrastructure and health care issues including prescription drug prices “dominated the lobbying agendas of some of the biggest spenders on K Street early this year.” Here’s Roll Call’s look at the top lobbying spenders so far this year:
Can You Fix Social Security? A New Tool Lets You Try
The Congressional Budget Office released an interactive tool Wednesday that shows how some widely discussed policy changes would affect the long-run financial health of the Social Security system.
“This interactive tool allows the user to explore seven policy options that could be used to improve the Social Security program’s finances and delay the trust funds’ exhaustion,” CBO said. “Four options would reduce benefits, and three options would increase payroll taxes. The tool allows for any combination of those options. It also lets the user change implementation dates and choose whether to show scheduled or payable benefits. … The tool also shows the impact of the options on different groups of people.”
Click here to view the interactive tool on the CBO website.
Why Prescription Drug Prices Keep Rising – and 3 Ways to Bring Them Down
Prescription drug prices have been rising at a blistering rate over the last few decades. Between 1980 and 2016, overall spending on prescription drugs rose from about $12 billion to roughly $330 billion, while its share of total health care spending doubled, from 5% to 10%.
Although lawmakers have shown renewed interest in addressing the problem, with pharmaceutical CEOs testifying before the Senate Finance Committee in February and pharmacy benefit managers (PBMS) scheduled to do so this week, no comprehensive plan to halt the relentless increase in prices has been proposed, let alone agreed upon.
Robin Feldman, a professor at the University of California Hastings College of Law, takes a look at the drug pricing system in a new book, “Drugs, Money and Secret Handshakes: The Unstoppable Growth of Prescription Drug Prices.” In a recent conversation with Bloomberg’s Joe Nocera, Feldman said that one of the key drivers of rising prices is the ongoing effort of pharmaceutical companies to maintain control of the market.
Fearing competition from lower-cost generics, drugmakers began over the last 10 or 15 years to focus on innovations “outside of the lab,” Feldman said. These innovations include paying PBMs to reduce competition from generics; creating complex systems of rebates to PBMs, hospitals and doctors to maintain high prices; and gaming the patent system to extend monopoly pricing power.
Feldman’s research on the dynamics of the drug market led her to formulate three general solutions for the problem of ever-rising prices:
1) Transparency: The current system thrives on secret deals between drug companies and middlemen. Transparency “lets competitors figure out how to compete and it lets regulators see where the bad behaviors occur,” Feldman says.
2) Patent limitations: Drugmakers have become experts at extending patents on existing drugs, often by making minor modifications in formulation, dosage or delivery. Feldman says that 78% of drugs getting new patents are actually old drugs gaining another round of protection, and thus another round of production and pricing exclusivity. A “one-and-done” patent system would eliminate this increasingly common strategy.
3) Simplification: Feldman says that “complexity breeds opportunity,” and warns that the U.S. “drug price system is so complex that the gaming opportunities are endless.” While “ruthless simplification” of regulatory rules and approval systems could help eliminate some of those opportunities, Feldman says that the U.S. doesn’t seem to be moving in this direction.
Read the full interview at Bloomberg News.